Note: This story was updated from an earlier version to more accurately describe the gene cloning technique that NaPro is acquiring from Pangene.
NEW YORK, Jan. 27-NaPro BioTherapeutics has purchased Pangene's genomics business, NaPro said today.
NaPro will assume of Pangene's genomics business, including equipment, software, licenses, patents and intellectual property relating to its homologous recombination technology and gene isolation services. The division will be physically relocated to NaPro's genomics center in Newark, Del.
Some Pangene genomics staff will also be transferred to NaPro, and others will remain in other capacities with Pangene, said NaPro genomics division president Jeffrey White. He declined to give further details about personnel changes.
Financial details of the acquisition were not disclosed.
Part of that portfolio includes Pangene's GeneGin Cloning System, an automated method to isolate and clone cDNAs without using conventional gene library-screening techniques.
The acquisition allows NaPro to offer full length gene isolation services, said White. "They are in the same field of gene repair and gene alteration, so there's a real nice fit there."
Pangene is based in Fremont, Calif. It is privately owned.